KORU Medical Systems Appoints Josh Bennett VP Global Commercialization
July 08 2020 - 8:30AM
Business Wire
Repro Med Systems, Inc. d/b/a KORU Medical Systems (NASDAQ:
KRMD) (“KORU Medical”) today announced the appointment of Josh
Bennett to the newly created position of Vice President Global
Commercialization. Mr. Bennett brings 20 years of healthcare
management and consulting experience to KORU Medical. He will be
responsible for creating and executing initiatives designed to
accelerate KORU Medical’s growth, with a focus on business
development and product commercialization. Mr. Bennett will report
directly to Don Pettigrew, President and CEO of KORU Medical.
Mr. Bennett’s experience spans healthcare product categories,
care settings, and end markets, including medical devices /
technology, pharmaceuticals, biologics, acute care, and home care.
He has been responsible for growth in both U.S. and international
markets.
He joins KORU Medical from Salter Labs, a global anesthesia and
respiratory medical device manufacturer, where he served as Vice
President Sales, Marketing, and Business Development beginning in
2012. Salter Labs merged with SunMed in 2019. Prior to this, he was
with Baxter Healthcare, a Fortune 500 diversified global
pharmaceutical and device manufacturer. At Baxter he focused on
pharmaceuticals and biologics, with an emphasis on product and
market development addressing nutrition, hydration, and hemophilia.
Mr. Bennett began his career at PwC Consulting (now IBM Global
Business Services).
Mr. Bennett received his MBA from the Kellogg School of
Management at Northwestern University, where he was a Siebel
Scholar and recipient of the Richard M. Clewett Award, and his BBA
from Northwood University.
“Josh brings knowledge, experience and industry contacts to KORU
Medical at a time of expanding opportunity,” said Don Pettigrew.
“He has a broad and proven record of building marketing programs
and creating new sales channels domestically and internationally
that deliver strong results. We believe that Josh’s skills align
well with our goals of identifying new and adjacent market
opportunities, expanding the therapeutic and pharmaceutical
applications of our Freedom60 integrated infusion system, and
leveraging what we view as significant advantages of
self-administered at-home infusion therapy.”
“I am excited to join KORU Medical at a time of significant
growth and market capture potential,” said Mr. Bennett. “I look
forward to collaborating with the team to expand KORU Medical’s
patient-focused platform and advance the company’s long-term growth
strategy.”
About KORU Medical
KORU Medical manufactures and commercializes innovative and
easy-to-use specialty infusion solutions that improve quality of
life for patients around the world. The FREEDOM Syringe Infusion
System currently includes the FREEDOM60® and FreedomEdge® Syringe
Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo
Subcutaneous Safety Needle Sets™. These devices are used for
infusions administered in the home and alternate care settings. For
more information about the Company, please visit
www.korumedical.com.
Forward-looking
Statements
This press release may contain forward-looking statements that
involve risks and uncertainties, identified by words such as
“will”, “believe” and “view”. Actual results may differ materially
from the results predicted and reported results should not be
considered as an indication of future performance. The potential
risks and uncertainties that could cause actual results to differ
from the results predicted include, among others, those risks and
uncertainties included under the captions “Risk Factors” in our
Annual Report on Form 10-K for the year ended December 31, 2019, as
amended, and our most recent Quarterly Report on Form 10-Q for the
quarter ended March 31, 2020, which are on file with the SEC and
are available on our website at www.korumedical.com/investors and
on the SEC website at www.sec.gov. Undue reliance should not be
placed on the forward-looking statements in this press release,
which are based on information available to us on the date hereof.
We undertake no duty to update this information unless required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200708005514/en/
The Equity Group Inc.
Devin Sullivan Senior Vice President 212-836-9608
dsullivan@equityny.com
Kalle Ahl, CFA Vice President 212-836-9614 kahl@equityny.com
KORU Medical Systems (NASDAQ:KRMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
KORU Medical Systems (NASDAQ:KRMD)
Historical Stock Chart
From Sep 2023 to Sep 2024